NFKB1 and ovarian cancer: Helenalin has been reported to suppress the expression of NF-κB p65 in ovarian cancer cells [16] or abrogate NF-κB signalling by inhibiting DNA binding activity of p65 in several cell lines including leukemia Jurkat (J16) cells [46] and hepatic stellate (HSC-T6) cells [67].